consumer genomics

By Jonah Comstock May 20, 2019
MyHeritage, an Israeli company that has been doing ancestry-related genetic testing since 2016, has announced a new product that brings the company into the health-focused consumer DNA testing space alongside the likes of 23andMe. MyHeritage DNA Health+Ancestry is a single test that includes a wide-range of genetic aptitudes for possible health conditions: specifically, the company will offer 11...
By Jonah Comstock March 27, 2019
Direct-to-consumer gene tests like Ancestry.com and 23andMe are increasingly informing consumers about gene alterations that could signal health risks. But those tests look at only a few positions on particular genes, as opposed to medical sequencing that is much more thorough. And, according to a 2018 study by Ambry Genetics in Genetics in Medicine, these results can be wrong — the study showed...
By Jonah Comstock March 11, 2019
At SXSW in Austin this weekend, consumer genomics company 23andMe unveiled its latest test, a predisposition report on Type 2 diabetes. The test, which has not undergone FDA clearance and does not purport to diagnose a condition, is designed to help people understand when they’re at a higher-than-normal risk for Type 2 diabetes so they can alter their lifestyle. To assist with the latter piece,...
By Dave Muoio November 15, 2018
Tattoo circuits. Researchers from Carnegie Mellon University and the University of Coimbra have unveiled a method of printing thin circuits that could better enable wearable computation. The low-cost alloy is attached to a stretchable tattoo paper that adheres to the skin when wet, similarly to the decorative tattoos worn by children. "This is a breakthrough in the printed electronics area,"...

Photo credit: Helix

By Laura Lovett October 19, 2018
Yesterday morning Helix, an early player in the consumer genomics field, announced the launch of its DNA Product Studio. The tool aims to boost the development of new genomics apps and tests for Helix’s partners.  Helix’s model uses third party partners that are experts in a specific arena to develop products. Meanwhile Helix provides sample collection, DNA sequencing, and secures data that the...
By Laura Lovett September 10, 2018
From ancestry to wine pallet preferences, consumer genomics have fueled both popular curiosity and public discourse. Now MyVytalics, a relative newcomer in the space that focuses on healthy aging, is teaming up with major player in the consumer genomics space Helix to release a new personal genomics app that will look at how genes play in to sleep patterns and nutrition. In the future, the two...
By Dave Muoio August 24, 2018
23andMe has emailed developers a warning that an API permitting use of anonymized customer datasets for third-party app development will be shut down in approximately two weeks, CNBC reports. While the raw data will remain available to clinical research partners such as GlaxoSmithKline, which invested $300 million this year to gain access to the genetic testing startup’s DNA database for drug...
23andMe lands $300 million investment from GlaxoSmithKline

23andMe kits at a Beverly Hills event in 2017. Credit: Matt Winkelmeyer, Getty Images

By Bernie Monegain July 25, 2018
23andMe on Wednesday announced that GlaxoSmithKline has invested $300 million to gain exclusive access to the genetic testing startup’s DNA database.  The deal comes as GlaxoSmithKline amid reports that GSK is weighing the possibility of a company breakup and investors contending that synergies between consumer markets and big pharma are inherently limited and that GSK’s pharmaceuticals business...

Scientist working in the lab at Helix. Photo courtesy of Helix. 

By Laura Lovett June 15, 2018
In the last few years consumer genomics has grown in both its offerings and legitimacy. The industry that was once best known for telling clients if they were Italian or Hungarian is now securing its foothold within the healthcare space.    Whether it is uniting women switched at birth 72-years prior or settling neighborly feuds, consumer genomics have caught the public’s interest. The highest...
By Jonah Comstock June 4, 2018
As of tomorrow, individual genetic risk tests are officially exempt from requiring 510(k) premarket approval, provided the company offering the test has gone through a one-time premarket review of its testing apparatus and at least one test. The notice, which will be officially published tomorrow in the Federal Registry, finalizes a guidance that was originally proposed in November 2017. "Today,...
виагра таблетки применение

купить таблетки сиалис

www.rs-clinic.com.ua